Bipolar disorder Personality disorders Sleep and mental health 
Psychiatric Times
JUNE 25, 2025
Developed with input from international mental health professionals, the BPD-I™ is freely available for clinical use, education, and research. SHOW MORE Discover the innovative Borderline Personality Disorder Inventory (BPD-I™), a psychodynamically-informed tool for assessing BPD symptoms effectively.
Psychiatric Times
JUNE 23, 2025
1 The newly announced CNPV pathway was introduced by FDA Commissioner Marty Makary, MD, MPH, on June 17, 2025, and is intended to expedite reviews for medications that address US public health priorities. The CNPV program, introduced by FDA Commissioner Marty Makary, aims to reduce review times to 1-2 months for eligible applications.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Psychiatric Times
JUNE 27, 2025
Ms Barbee has a passion to reduce the stigma around mental health and promoting increased access to mental health care and education of both clinicians and the general public. She has also served as advisory board participant for Supernus Pharmaceuticals and Axsome Therapeutics.
Psychiatric Times
JUNE 24, 2025
A Harmful Dysfunction Analysis Author(s): Jean-Arthur Micoulaud-Franchi, MD, PhD , Christophe Gauld, MD, PhD +2 More Key Takeaways Sleep medicine lacks a structured definition for disorders, complicating diagnosis and classification compared to psychiatry's DSM framework. SHOW MORE What is a sleep disorder?
Psychiatric Times
JUNE 13, 2025
of patients who were prescribed antipsychotics for their psychiatric illness and had evidence of tardive dyskinesia (TD) had TD recorded properly in their electronic health records, supporting the idea that TD is often underreported and misdiagnosed and, therefore, not treated appropriately.
Psychiatric Times
JULY 1, 2025
SHOW MORE The FDA will update ADHD medication labels, warning of weight loss risks in children under 6, urging careful monitoring by health care professionals. Healthcare professionals should monitor weight and growth in young patients on these medications and consider alternative treatments if adverse effects occur.
Psychiatric Times
JUNE 30, 2025
Compass Pathways' COMP360 psilocybin has shown significant efficacy in a phase 3 trial for treatment-resistant depression, advancing psychedelic research in mental health. NRx Pharmaceuticals seeks FDA approval for NRX-100, a preservative-free ketamine for suicidal depression and PTSD, via the National Priority Voucher pathway.
Expert insights. Personalized for you.
141 
Let's personalize your content